Innovision IPO sees tepid response on Day 4; subscribed 0.31 times, GMP signals flat listing
Analysis of this story by livemint_markets · 13 Mar 2026, 7:11 PM IST (about 2 months ago)
AI Analysis
Weak IPO demand for a pharma company suggests cautious investor sentiment towards new issues, potentially impacting other upcoming IPOs.
Trading Insight
Bearish for new listings, especially those with weak initial subscription.
Quick check: SUNPHARMA bullish bias (-1.4% 1d), CIPLA bearish bias (-0.6% 1d).
Key Evidence
- •Innovision Limited's IPO subscribed only 0.31 times.
- •Bids for 19.08 lakh shares against 61.51 lakh offered.
- •Company extended bidding period and lowered price band.
- •GMP signals flat listing.
- •Risk flag: Poor market sentiment for IPOs
Affected Stocks
Sectors:pharma
Sources and updates
Original source: livemint_markets
Published: 13 Mar 2026, 7:11 PM IST
Last updated on Anadi News: 13 Mar 2026, 7:20 PM IST
AI-powered analysis by
Anadi Algo News